98534-83-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-METHOXYPHENYL)-5-(TRIFLUOROMETHYL)& is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of drugs with novel mechanisms of action and potential therapeutic benefits.
Used in Medicinal Chemistry Research:
1-(4-METHOXYPHENYL)-5-(TRIFLUOROMETHYL)& is used as a key building block in the design and synthesis of new drug candidates. Its incorporation into drug molecules can lead to improved pharmacokinetic properties, such as enhanced solubility, bioavailability, and stability.
Used in Drug Discovery:
1-(4-METHOXYPHENYL)-5-(TRIFLUOROMETHYL)& is used as a starting material in the search for new therapeutic agents. Its chemical versatility enables the exploration of various structural modifications, which can result in the identification of promising drug candidates with improved efficacy and safety profiles.
Used in Drug Development:
1-(4-METHOXYPHENYL)-5-(TRIFLUOROMETHYL)& is used as a component in the formulation of new drugs. Its unique properties can contribute to the overall performance of the drug, such as enhancing target selectivity, reducing side effects, and prolonging the duration of action.

InChI:InChI=1/C12H9F3N2O3/c1-20-8-4-2-7(3-5-8)17-10(12(13,14)15)9(6-16-17)11(18)19/h2-6H,1H3,(H,18,19)

Upstream product

• 571-55-1 ethyl 2-(ethoxymethylidene)-4,4,4-trifluoro-3-oxobutanoate 
• 19501-58-7 4-methoxyphenylhydrazine hydrochloride 
• 112055-38-6 ethyl 1-(4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 

Relevant academic research and scientific papers

Discovery of Novel Inhibitors of Uridine Diphosphate- N-Acetylenolpyruvylglucosamine Reductase (MurB) from Pseudomonas aeruginosa, an Opportunistic Infectious Agent Causing Death in Cystic Fibrosis Patients

Pseudomonas aeruginosa is of major concern for cystic fibrosis patients where this infection can be fatal. With the emergence of drug-resistant strains, there is an urgent need to develop novel antibiotics against P. aeruginosa. MurB is a promising target

Synthesis and photoluminescence analysis of europium(III) complexes with pyrazole acid and nitrogen containing auxiliary ligands

Four red photoluminescent europium(III) complexes have been synthesized by using fluorinated carboxylate ligand, 1-(4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid as main ligand and bathophenanthroline, 1,10-phenanthroline and 2,2-bipy

SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS

Disclosed are compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is formula (II) Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Synthesis of 1-Aryl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic Acids and Esters

Ethyl 1-aryl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylates 2 were prepared by the condensation of arylhydrazines with ethyl 3-ethoxy-2-(trifluoroacetyl)-2-propenoate (1a) at low temperature.The corresponding acids were also synthesized.X-ray diffraction analysis of an amide derivative 4 verified the position of the trifluoromethyl group on the pyrazole ring.